President Trump recently announced that his administration has successfully negotiated lower prices for certain weight loss medications with drug manufacturers Novo Nordisk and Eli Lilly. These agreements will result in reduced prices for glucagon-like peptide-1 drugs, such as Zepbound and Wegovy, which will be available on the TrumpRx platform starting in January 2026. The initial prices are set at $345 per month, with a projected decrease to $250 by 2028.
While the $345 price tag is being touted as a most-favored nation price, it falls short of meeting the criteria set by the Trump administration earlier this year. This price is still lower than the current market prices for these medications, which are sold at $499 per month directly to consumers. However, for patients with insurance coverage, the impact of TrumpRx may be minimal as their monthly co-payments are already lower than $100.
Under the agreements, Novo Nordisk and Eli Lilly have agreed to sell the medications to Medicaid and Medicare for $245 per month, with a $50 co-payment for Medicare beneficiaries. It remains unclear whether this $245 price aligns with the maximum fair price negotiated under the Inflation Reduction Act, as details on this price are still undisclosed.
The agreements also include provisions for Medicare and Medicaid to extend coverage to patients with obesity who are at high metabolic or cardiovascular risk. This includes patients with specific BMI levels and certain co-morbidities, although the extent of coverage expansion remains uncertain.
In exchange for the lower prices, Novo Nordisk and Eli Lilly will receive tariff reprieves and priority review vouchers. These agreements are part of the Trump administration’s broader efforts to lower drug prices and increase access to medications for patients. Previous deals with other pharmaceutical companies have also resulted in discounted prices for Medicaid and Medicare, as well as the launch of new drugs at most-favored nation prices.
The impact of these agreements on stakeholders in the pharmaceutical supply chain and patients is yet to be fully realized. The confidentiality of the deals makes it challenging to assess their implications, and the lack of transparency raises questions about the long-term effects of these negotiations.
